Point72 Asset Management
ONCT

Point72 Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Point72 Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,172
Closed -$1.78M – 1232
2020
Q4 		$1.78M Buy
+18,172
New +$1.15M 0.01% 746
2018
Q3 		– Sell
-1,216
Closed -$2.61M – 1270
2018
Q2 		$2.61M Buy
1,216
+445
+58% +$1.13M 0.01% 727
2018
Q1 		$1.92M Buy
+771
New +$1.72M 0.01% 739

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Point72 Asset Management's ONCT Position: Q1 2021 in Review

Point72 Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2021, closing a stake of 18,172 shares — an estimated $1.78M sold.

Point72 Asset Management first reported a position in ONCT in Q1 2018 and held it in 3 quarters. The position peaked at $2.61M in Q2 2018. 64 funds tracked by Wall St. Rank hold ONCT as of Q1 2021.

  • Point72 Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Point72 Asset Management sold 18,172 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.78M.
  • Point72 Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Point72 Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $2.61M in Q2 2018.
  • 64 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Point72 Asset Management's 13F filing for Q1 2021, filed 17 May 2021.